Filing Details

Accession Number:
0001225208-13-017528
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-08 16:44:46
Reporting Period:
2013-08-07
Filing Date:
2013-08-08
Accepted Time:
2013-08-08 16:44:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1385187 Covidien Plc COV Surgical & Medical Instruments & Apparatus (3841) 980624794
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1400563 J Charles Dockendorff C/O Covidien
15 Hampshire Street
Mansfield MA 02048
Evp & Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2013-08-07 35,572 $41.66 173,782 No 4 M Direct
Ordinary Shares Acquisiton 2013-08-07 31,816 $31.16 205,598 No 4 M Direct
Ordinary Shares Acquisiton 2013-08-07 27,409 $33.76 233,007 No 4 M Direct
Ordinary Shares Disposition 2013-08-07 94,797 $63.15 138,210 No 4 S Direct
Ordinary Shares Disposition 2013-08-08 391 $63.71 137,819 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2013-08-07 35,572 $0.00 35,572 $41.66
Ordinary Shares Stock Option (Right to Buy) Disposition 2013-08-07 27,409 $0.00 27,409 $33.76
Ordinary Shares Stock Option (Right to Buy) Disposition 2013-08-07 31,816 $0.00 31,816 $31.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-03-09 No 4 M Direct
0 2015-11-21 No 4 M Direct
0 2018-12-01 No 4 M Direct
Footnotes
  1. Includes unvested restricted stock units and associated unvested dividend equivalent units, the number of which were adjusted in connection with the recent spin-off of Covidien's pharmaceuticals business.
  2. The price reported is the weighted average price. Shares were sold in multiple transactions at prices ranging from $63.04 to $63.34. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares sold at each price.
  3. Adjusted in connection with the spin-off of Covidien's pharmaceuticals business.
  4. Options became exercisable in equal installments on each of the first, second, third and fourth anniversary of the grant date.